Exclusive Summary

• • Global BIC APOC3-siRNA with superior Potency and durability at low dose.
• • Excellent APOC3-siRNA data from ongoing Ph 1 trial: superior efficacy and long-lasting effect with yearly-dosing potential (vs Plozasiran Q3M).
• • No traditional DDI concern with combination usage of small molecules.

Asset Materials

Contact Us for Full Materials